Reference health
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
66/66 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
7 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 66 checked references that resolve
resolves10.3899/jrheum.110241
Mortality Profile Related to Systemic Lupus Erythematosus: A Multiple Cause-of-death Analysis
resolves10.1016/j.medcli.2010.11.032
Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry
resolves10.1038/nrneph.2012.107
Complications of long-term therapy for ANCA-associated systemic vasculitis
resolves10.1136/ard.2008.091926
European biologicals registers: methodology, selected results and perspectives
resolves10.1001/jama.1966.03100200057018
Acute Septic Arthritis Complicating Chronic Rheumatoid Arthritis
resolves10.1002/anr.1780320422
Infectious arthritis complicating rheumatoid arthritis and other chronic rheumatic disorders
resolves10.1136/ard.49.6.363
Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients.
resolves10.1136/ard.2006.057265
Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis
resolves10.1136/bmj.290.6484.1797
Ten year mortality and causes of death in patients with rheumatoid arthritis.
resolves10.1136/ard.61.11.994
Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study
resolves10.1002/art.10524
Frequency of infection in patients with rheumatoid arthritis compared with controls: A population‐based study
resolves10.1002/art.24176
Association of the TRAF1/C5 locus with increased mortality, particularly from malignancy or sepsis, in patients with rheumatoid arthritis
resolves10.1136/ard.2011.151043
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
resolves10.1002/art.21978
Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register
resolves10.1002/art.21568
Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease‐modifying antirheumatic drugs, and anti–tumor necrosis factor therapy
resolves10.1002/art.27555
Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry
resolves10.1002/art.22504
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists
resolves10.1136/ard.2008.089276
Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry
resolves10.1002/art.1780401106
Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis. Results from a primary care‐based incident case‐control study in Norfolk, England
resolves10.1002/art.21575
A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullination
resolves10.1038/nri2530
How cigarette smoke skews immune responses to promote infection, lung disease and cancer
resolves10.1136/ard.2010.128637
High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis
resolves10.1093/rheumatology/kem076
Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis
resolves10.1186/ar3453
The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses
resolves10.1136/annrheumdis-2011-200336
Comparative study of MRI and power Doppler ultrasonography of the heel in patients with spondyloarthritis with and without heel pain and in controls
resolves10.1136/ard.2005.048371
Safety of extended treatment with anakinra in patients with rheumatoid arthritis
resolves10.1002/art.34530
Development and validation of a risk score for serious infection in patients with rheumatoid arthritis
resolves10.1097/MD.0b013e318211106a
TNF-α Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid Arthritis
resolves10.1136/annrheumdis-2011-200702
Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis
resolves10.1001/jama.295.19.2275
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies
resolves10.1136/ard.2008.091025
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events
resolves10.1002/art.30310
Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials
resolves10.1136/ard.2007.083188
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
resolves10.1093/rheumatology/keq343
Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
resolves10.1016/j.jaad.2010.09.734
The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials
resolves10.1136/ard.2008.098822
Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials
resolves10.1002/art.22193
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trials
resolves10.1002/sim.2528
Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events
resolves10.1002/art.21386
Infections in patients with rheumatoid arthritis treated with biologic agents
resolves10.1002/art.22600
Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
resolves10.1002/art.22808
Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies
resolves10.1136/ard.2006.062760
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
resolves10.1136/ard.2011.152769
Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register
resolves10.1001/jama.2011.1692
Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
resolves10.1056/NEJMoa011110
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
resolves10.1086/421494
Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor
resolves10.1002/art.11137
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active‐surveillance report
resolves10.1002/art.21137
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
resolves10.1136/ard.2009.118935
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
The 7 references without a DOI — listed, not checked
no DOI — not checked3_33159443
no DOI — not checked12_44318293
no DOI — not checked19_15989587
no DOI — not checked22_30824584
no DOI — not checked28_42073072
no DOI — not checked32_44318294
no DOI — not checked69_17718748
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1093/rheumatology/kes305"><img src="https://citestamp.com/citestamped/10.1093/rheumatology/kes305/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1093/rheumatology/kes305)